The company develops engineered adenoviral vectors for targeted gene delivery in immuno-oncology applications, enabling precise modulation of cellular responses. This technology facilitates the discovery of potent new drugs by enhancing the specificity and efficacy of therapeutic interventions in cancer treatment.
Funding
$30M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Targeted gene delivery in immuno-oncology faces challenges in achieving precise modulation of cellular responses, which limits the specificity and efficacy of therapeutic interventions in cancer treatment. Traditional methods often lack the necessary control to selectively target and modify immune cells within the tumor microenvironment.
Solution
The company develops engineered adenoviral vectors designed for targeted gene delivery in immuno-oncology applications. These vectors enable precise modulation of cellular responses, enhancing the specificity and efficacy of therapeutic interventions in cancer treatment. By engineering the adenoviral vectors, the company aims to improve the delivery of therapeutic genes to specific immune cells within the tumor microenvironment, leading to more effective and targeted cancer therapies. This approach facilitates the discovery of potent new drugs by optimizing the interaction between the vector and the target cell.
Target Audience
The primary target audience includes pharmaceutical companies and research institutions involved in immuno-oncology drug discovery and development.
Features
- Engineered adenoviral vectors for targeted gene delivery
- Precise modulation of cellular responses
- Enhanced specificity and efficacy of therapeutic interventions
- Optimized interaction between the vector and the target cell